Fuse Vectors
Henrik Stage is an accomplished executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Executive Chair and Co-founder of Fuse Vectors since January 2023, Henrik also holds advisory and board roles at Notify Therapeutics and Biomia Aps, as well as being a board member for ResoTher Pharma. As the founder and CEO of Adcendo since January 2017, Henrik leads efforts to develop novel antibody-drug-conjugates for cancer treatment. Previously, Henrik served as CFO for RhoVac ApS and Synact Pharma ApS, and CEO and CFO at Santaris Pharma A/S, where significant funding and partnership agreements were secured. Educationally, Henrik holds a Master’s degree in Finance from Copenhagen Business School and attended Rysensteen Gymnasium.
This person is not in any teams
Fuse Vectors
At Fuse Vectors, our mission is to revolutionize AAV gene therapy development. Traditional cell-based technologies have hindered progress, posing challenges in safety, efficacy, development time, and cost. Our Cell-Free AAV technology surpasses these methods, producing safer, more effective, and cost-efficient AAV viral vectors in a fraction of the time.